Pharmafile Logo
Pharmafocus logo
Advanced Search

Grunenthal

Showing 11 posts of 11 posts found.

Grünenthal receives FDA Breakthrough Therapy Designation for knee osteoarthritis drug

May 23, 2023
Medical Communications Breakthrough Therapy Designation, FDA, Grunenthal, Musculo-skeletal disorder, osteoarthritis

German pharmaceutical company Grünenthal has announced that the US Food and Drug Administration (FDA) has awarded it Breakthrough Therapy Designation …

News
shutterstock_138095450

Grünenthal buys European rights to AstraZeneca’s Crestor for a potential $350m

December 1, 2020
Manufacturing and Production, Sales and Marketing AstraZeneca, Crestor, Grunenthal

Grünenthal has picked up AstraZeneca’s statin therapy Crestor (rosuvastatin), currently approved in dyslipidaemia and hypercholesterolaemia treatment, in a deal worth …

News
mundipharma

Mundipharma signs Chinese licensing and distribution agreement with Grünenthal

January 16, 2018
Manufacturing and Production China, Grunenthal, Mundipharma, Tramal, pharma

US-based firm Mundipharma is set to take over commercialisation and distribution duties for the analgesic Tramal (tramadol) in China on …

News
shutterstock_92671375

Five major pharma firms break ABPI code of conduct, according to watchdog

December 15, 2016
Medical Communications, Sales and Marketing ABPI, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Grunenthal, Janssen

Eli Lilly, Boehgringer Ingelheim, AstraZeneca UK, Grunenthal and Janssen-Cilag have been “named and shamed” by the Prescription Medicines Code of …

News
astrazeneca_plaque

AstraZeneca licenses gout drug Zurampic to Grünenthal in Europe and Latin America

June 2, 2016
Business Services, Manufacturing and Production, Sales and Marketing AstraZeneca, Grunenthal, Licencing, Zurampic, gout, sales

UK drugmaker AstraZeneca (LSE: AZN) on Thursday said it has entered into a licensing agreement worth up to $230 million …

News
Tapentadol

Grünenthal and Vifor breach Code

July 20, 2012
Sales and Marketing ABPI, Grunenthal, PMCPA, Vifor, code, tapentadol

Grünenthal and Vifor Pharma UK have been named and shamed for serious infringements of the ABPI Code of Practice. Adverts …

News

Grunenthal in talks to sell pain drug portfolio

May 19, 2011
Sales and Marketing Grunenthal, Stada, chronic pain, pain therapeutics

Grunenthal is negotiating a 360 million euro deal to sell Central and Eastern European rights to some of its pain …

News

Jango to manage Grünenthal pain awards

February 3, 2011
Medical Communications Grunenthal, Jango, awards, disease awareness campaigns

Jango Communications has been appointed by Grünenthal to manage the Pain Awards Programme they are sponsoring this year. German-based Grünenthal, …

News
ABPI

Novo rebuked after diabetes promotion breaches Code

December 16, 2010
Medical Communications ABPI, ABPI Code of Practice, Grunenthal, Napp Pharmaceuticals, Novo Nordisk, PMCPA, diabetes, diabetes drug marketing, lilly

Novo Nordisk been ‘named and shamed’ in health trade journal advertisements this week for breaching the ABPI Code of Practice. …

News

Grünenthal breaches Code with off-label promotion

September 28, 2010
Medical Communications Code of Practice, Grunenthal, PMCPA, Versatis

Grünenthal has been severely criticised in two rulings by UK pharma’s self-regulatory body the PMCPA for promoting off-label use of …

News

Grunenthal’s new pain treatment approved in US

November 27, 2008
Sales and Marketing Grunenthal

The first new oral centrally acting analgesic in more than 25 years has been approved in the US.Tapentadol was developed …

News

Latest content

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

September 28, 2023

Avalyn Pharma raises $175m in Series C financing for inhalation therapies

September 28, 2023

NMD Pharma begins phase 2 trial for spinal muscular atrophy treatment

September 27, 2023

Alfasigma to acquire Intercept Pharmaceuticals for $19 per share

September 27, 2023

Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review

September 26, 2023